吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价

何志高; 鲍思蔚; 翟晓波

doi:10.3969/j.issn.1006-0111.2012.02.015

吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价

doi: 10.3969/j.issn.1006-0111.2012.02.015

上海市东方医院药学部, 上海 200120

基金项目: "浦东新区卫生系统医学领先人才培训项目"(PWRd2007-12)资助.

Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

Department of pharmacy, Shanghai east hospital, Shanghai 200120, China

摘要: 目的利用Meta分析评价吉西他滨、长春瑞滨联合顺铂治疗晚期非小细胞肺癌的有效性与安全性。方法检索Pubmed数据库和CHKD数据库,纳入随机对照试验,用专用软件Review Manager Version4.2.2进行系统评价。结果共有7个英文期刊文献研究1 561例患者,10个中文期刊文献研究864例患者纳入系统评价。英文期刊文献Meta分析结果显示吉西他滨+顺铂方案与长春瑞滨+顺铂方案在总缓解率上无区别,在一年生存率上吉西他滨+顺铂方案方案优于长春瑞滨+顺铂方案,中文期刊文献Meta分析结果显示两套方案在总缓解率和一年生存率上均无显著性差异。关于毒性反应方面的报道,中英文期刊文献Meta分析结果一致,吉西他滨+顺铂方案中性粒细胞减少发生率低于长春瑞滨+顺铂方案,血小板减少发生率高于长春瑞滨+顺铂方案,恶心呕吐发生率差异无统计学意义。结论中英文期刊文献在评价吉西他滨、长春瑞滨联合顺铂治疗晚期非小细胞肺癌的有效性上有区别。应重视提高中文期刊随机对照研究文献的质量,同时在晚期非小细胞肺癌治疗过程中,应结合患者具体情况,选择对患者生活质量影响较小的方案。
- 晚期非小细胞肺癌 /
- 化学治疗 /
- 吉西他滨 /
- 长春瑞滨 /
- 顺铂 /
- Meta分析
Abstract: Objective To compare and evaluate the effectiveness and security of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer by Meta-analysis. Methods PubMed database and CHKD database were searched, included in randomized controlled trials. Special software Review Manager Version 4.2.2 was used to systematic reviews. Results Seven studies of English journals involving 1 561 patients and ten studies of Chinese journals involving 864 patients were included. There was no difference in the overall response from gemcitabine versus vinorelbine in combination with cisplatin by Meta-analysis of English and Chinese journals. But the project of gemcitabine+cisplatin was superior to vinorelbine+cisplatin in 1-year survival rate of English journals and there was no difference in 1-year survival rate by Meta-analysis of Chinese journals. Both English and Chinese journals showed the same reports of toxicity. The incidence rate of neutropenia was higher in vinorelbine+cisplatin, and the thrombocytopenia was higher in gemcitabine + cisplatin, nausea and vomiting and nervous system response were no significant difference between two groups. Conclusions The effectiveness of gemcitabine versus vinorelbine combined with cisplatin of advanced non-small cell lung cancer was different. Improving the quality of RCT in Chinese journals was very important.
- advanced non-small cell lung cancer /
- chemotherapy /
- gemcitabine /
- vinorelbine /
- cisplatin /
- Meta-znalysis

[1]	Novello S,Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1 :Early-stage disease[J].Oncol (Williston Park),2003,17(3):357.
[2]	Alberti W.Chemotherapy in non-small-cell lung cancer:a meta-analysis using updated data on individual patients from 52 randomized clinical trials Non-small Cell Lung Cancer Collaborative Group[J].BMJ,1995,311(7010):899.
[3]	Juni P, Altman DG, Egger M.Systematic reviews in health care: Assessing the quality of controlled clinical trials[J].BMJ,2001,323(7303):42.
[4]	Chang JW,Tsao TC,Yang CT,et al.A randomized study of gemcitabine plus cisplatin and vinorelbine plus cisplatin in patients with advanced non-small-cell lung cancer[J].Chang Gung Med J,2008,31(6):559.
[5]	Comeplla P, Frasci G, Panza N, et al.Randomized trial comparing cisplatin,gemcitabine,and vinorelbine in advanced non-small-cell lung cancer:interim analysis of a phase Ⅲ trial of the Southern Italy Cooperative Oncology Group[J].J Clin Oncol,2000,18(7):1451.
[6]	Gebbia V,Galetta D, Caruso M,et al.Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage ⅢB-Ⅳ non small cell lung carcinoma:a prospective randomized phase Ⅲ trial of the Gruppo Oncologico Italia Meridionale[J].Lung Cancer,2003,9(2):179.
[7]	Gridelli C,Maione P,Illiano A,et al.Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer:the MILES-2P studies[J].J Clin Oncol,2007,25(29):4663.
[8]	Martoni A, Marino A,Sperandi F,et al.Multicentre randomised phase Ⅲ study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer[J].Eur J Cance,2005,1(1):81.
[9]	Novello S,Kielhorn A,Stynes G,et al.Cost-minimisation analysis comparing gemcitabine/cisplatin,paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment advanced non-small cell lung cancer in Italy[J].Lung Cancer,2005,48(3):379.
[10]	Ohe Y,Ohashi Y,Kubota K,et al.Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel,cisplatin plus gemcitabine,and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:Four-Arm Cooperative Study in Japan[J].Ann Oncol,2007,18(2):317.
[11]	岳峥,李琳琳.GP方案和NP方案治疗晚期非小细胞肺癌疗效比较[J].实用肿瘤学杂志,2006,20(4):315.
[12]	张英.长春瑞滨联合顺铂治疗晚期非小细胞肺癌的疗效观察[J].临床肺科杂志,2011,16(11):1729.
[13]	时珠海.以顺铂为基础三种化疗方案治疗晚期非小细胞肺癌疗效观察[J].内科,2011,6(4):321.
[14]	赵文英,吉兆宁.顺铂加吉西他滨与顺铂加长春瑞滨一线治疗晚期非小细胞肺癌的对照研究[J].中国临床药理学与治疗学,2006,11(12):1408.
[15]	刘联,王秀问,黎莉,等.含顺铂的三组联合化疗方案治疗晚期非小细胞肺癌的随机对照临床研究[J].癌症,2006,25(8):990.
[16]	陈群,石琴,谢强,等.不同方案治疗晚期非小细胞肺癌的近期疗效观察[J].临床肺科杂志,2008,13(8):998.
[17]	宋昱晨.GP与NP方案治疗晚期非小细胞肺癌的临床对比观察[J].当代医学,2007,(10):68.
[18]	谢强,陈群,李育宏,等.GP和NP方案治疗晚期非小细胞肺癌的随机对照临床研究[J].临床肺科杂志,2008,13(2):160.
[19]	李兆元,黄秋华,徐海声,等.国产吉西他滨或长春瑞滨联合顺铂治疗进展期非小细胞肺癌的临床观察[J].现代肿瘤医学,2007,15(9):1255.
[20]	隋捷,刘积良,段寅,等.吉西他滨联合顺铂治疗晚期非小细胞肺癌的临床研究[J].中国肿瘤临床,2004,31(23):1349.
[21]	胡燕,徐传新.缬沙坦治疗轻、中度原发性高血压有效性与安全性的Meta分析 [J].中国药房,2008,19(2):128.
[22]	何志高,周东,舒丽芯.荟萃分析在头孢三嗪治疗下呼吸道感染中的应用[J].中国药房,2001,12(5):280.
[23]	林晓萍,王庆生.Meta-analysis在肿瘤循证医学中的应用[J].中国肿瘤临床(英文版),2008,5(1):1.

[1]	李锐, 张倩倩, 王瑞冬, 高小峰. 国家集中带量采购政策下样本医院良性前列腺增生治疗药物使用情况分析 . 药学实践与服务, 2025, 43(1): 41-46. doi: 10.12206/j.issn.2097-2024.202408031
[2]	杨志晖, 蔡华丹, 徐方楚, 刘园, 袁海龙. 临床药师参与人粒细胞刺激因子致弥漫性肺泡出血的病例分析 . 药学实践与服务, 2025, 43(11): 567-571. doi: 10.12206/j.issn.2097-2024.202506021
[3]	邵尉, 袁妮, 刘叶, 于飞, 柳莹, 王峰. 丙戊酸钠与左乙拉西坦治疗儿童癫痫病的成本-效果分析 . 药学实践与服务, 2025, 43(8): 1-5. doi: 10.12206/j.issn.2097-2024.202408046
[4]	曹奇, 张嘉宝, 王培. 基于无监督自动降维分析与手动圈门联用的骨骼肌髓系细胞多色流式分析方法 . 药学实践与服务, 2025, 43(7): 325-328, 366. doi: 10.12206/j.issn.2097-2024.202404077
[5]	钟玲, 曹金发, 何苗, 田泾. 晚期胃癌患者紫杉醇脂质体简化口服预处理方案的实践及分析 . 药学实践与服务, 2025, 43(): 1-4. doi: 10.12206/j.issn.2097-2024.202406047
[6]	王文涛, 高兴, 赵凤平, 郑灿辉, 陈新. 异硒唑酮类化合物在疾病治疗中的作用和化学合成方法 . 药学实践与服务, 2025, 43(8): 367-372. doi: 10.12206/j.issn.2097-2024.202308064
[7]	王晓丹, 刘文杰, 宋畅, 董文星, 赵倩, 马骁龙. 利多卡因凝胶贴膏联合普瑞巴林治疗带状疱疹后神经痛患者疗效及对血清疼痛介质的影响 . 药学实践与服务, 2025, 43(11): 572-576. doi: 10.12206/j.issn.2097-2024.202505036
[8]	赵雪, 顾妍秋, 楚皓文, 吴彩胜, 李镐, 陈啸飞. 基于超高效液相色谱-四极杆飞行时间质谱的麻杏石甘汤化学成分分析 . 药学实践与服务, 2025, 43(11): 548-554, 571. doi: 10.12206/j.issn.2097-2024.202306028
[9]	孟园园, 吴芸杨, 陈婷如, 顾秦五风, 杨延龙. 九味永安颗粒联合西替利嗪治疗湿疹湿热蕴肤证的临床疗效观察 . 药学实践与服务, 2025, 43(6): 298-302. doi: 10.12206/j.issn.2097-2024.202407045
[10]	胡越, 殷勇, 徐晓红, 施柳辉, 朱建勇, 年华. 基于网络药理学探讨夏枯草消瘤合剂治疗非小细胞肺癌的作用机制 . 药学实践与服务, 2025, 43(12): 1-8. doi: 10.12206/j.issn.2097-2024.202302020
[11]	陈官旭, 宋雨桐, 郭秀强, 张咪, 刘志宏, 宋洪涛. EGFR-TKIs单药及其联合方案在晚期非小细胞肺癌一线治疗中的疗效与安全性比较：网状Meta分析 . 药学实践与服务, 2025, 43(): 1-11. doi: 10.12206/j.issn.2097-2024.202504044
[12]	李娜, 黄诚文, 孙秀娟, 王晓红, 张丽, 王兴坡. 奥希替尼与吉非替尼治疗表皮生长因子受体突变的晚期非小细胞肺癌的成本效果分析 . 药学实践与服务, 2025, 43(12): 608-613. doi: 10.12206/j.issn.2097-2024.202411032
[13]	陈婷如, 顾秦五风, 吴芸杨, 孟园园, 杨延龙, 李睿旻. 中药外治法治疗湿疹引起皮肤瘙痒的Meta分析 . 药学实践与服务, 2025, 43(8): 383-389. doi: 10.12206/j.issn.2097-2024.202504013
[14]	杨凤艳, 张月, 陈恩贤, 缪雪蓉, 魏凯. 瑞马唑仑临床应用研究进展 . 药学实践与服务, 2024, 42(9): 365-374. doi: 10.12206/j.issn.2097-2024.202405026
[15]	石晓萍, 吕迁洲, 李晓宇, 许青. 泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050
[16]	张晶晶, 索丽娜, 郑兆红. 89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
[17]	崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺. 临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
[18]	王鹏, 陈顺, 赵逸, 高守红, 王志鹏. 卡培他滨致小鼠手足综合征模型的建立及评价 . 药学实践与服务, 2024, 42(9): 385-388, 398. doi: 10.12206/j.issn.2097-2024.202308045
[19]	宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅. 帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
[20]	刘丽艳, 余小翠, 孙传铎. 纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044

点击查看大图

计量

文章访问数: 6849
HTML全文浏览量: 424
PDF下载量: 354
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价

doi: 10.3969/j.issn.1006-0111.2012.02.015

Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

计量

吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价

doi: 10.3969/j.issn.1006-0111.2012.02.015

上海市东方医院药学部, 上海 200120

English Abstract

Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

Department of pharmacy, Shanghai east hospital, Shanghai 200120, China

全文HTML

目录

留言板

吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价

doi: 10.3969/j.issn.1006-0111.2012.02.015

Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

计量

出版历程

吉西他滨或长春瑞滨联合顺铂治疗晚期非小细胞肺癌的系统评价

doi: 10.3969/j.issn.1006-0111.2012.02.015

上海市东方医院药学部, 上海 200120

English Abstract

Meta-analysis of gemcitabine versus vinorelbine combined with cisplatin in treatment of advanced non-small cell lung cancer

Department of pharmacy, Shanghai east hospital, Shanghai 200120, China

全文HTML

目录